Metformin

Metformin Properties

Melting point	199-200 °C
Boiling point	229.23°C (rough estimate)
Density	1.0743 (rough estimate)
refractive index	1.5760 (estimate)
storage temp.	Keep in dark place,Inert atmosphere,Room temperature
solubility	Acetonitrile (Slightly), Aqueous Acid (Slightly), Dichloromethane (Slightly)
form	Solid
pka	pKa 2.8(H2O,t =32) (Uncertain)
color	White to Light Brown
Water Solubility	Water: 50 mg/mL (387.12 mM)
BCS Class	3
InChI	InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
InChIKey	XZWYZXLIPXDOLR-UHFFFAOYSA-N
SMILES	C(=N)(N(C)C)NC(=N)N
CAS DataBase Reference	657-24-9(CAS DataBase Reference)
EPA Substance Registry System	Imidodicarbonimidic diamide, N,N-dimethyl- (657-24-9)

SAFETY

Risk and Safety Statements

Symbol(GHS)	GHS07
Signal word	Warning
Hazard statements	H302
Precautionary statements	P264-P270-P301+P312-P330-P501
Toxicity	LD50 oral in mouse: 1450mg/kg

Metformin Chemical Properties,Uses,Production

History

Metformin is a biguanide compound which originated from the extraction of goat’s rue plants. The structure of metformin was identified by British scholars in the early 1920s. In 1922, Werner and Bell et?al. first synthesized metformin in 31 institutes in Dublin, Ireland. In 1929, Slotta and Tschesche found metformin’s hypoglycemic action. However, because of other potent antidiabetic drugs such as insulin which were widely used in clinical practice, the pharmacological effects of metformin didn’t receive much attention.
Until the 1950s, a French diabetic scientist Jean Sterne found the hypoglycemic effect of metformin through the study of galegine. Then the drug was used in diabetic patients for the first time, and the results were published in 1957. UKPDS, which began from 1977 and ended in 1997 and was then followed up for 10?years, is the longest in the history of clinical trials and has a significant impact on practice and guidelines for prevention and treatment of diabetes mellitus. In this trial, metformin was found to reduce the risk of diabetic complications by 32%. In addition, it was proved for the first time that metformin can reduce blood glucose and protect against cardiovascular function, especially in obese patients. In 1994, metformin was approved by the US FDA for type 2 diabetes treatment. Currently, metformin has become the world’s most widely used antidiabetic drug.
Aiming at improving the stability of the absorption of metformin, chemists have also carried out a series of structural renovation and modification. Metformin activates with carbonyl, esters, chlorides, and aldehydes to form triazine compounds, with 1,3-diketone to produce pyrimidine compounds, and with disulfides to produce C-S coupling products, etc.

Uses

non-insulin dependent diabetes mellitus

Indications

Metformin (Glucophage) was used in Europe for many years before it was approved for use in the United States in 1995. Metformin is the only approved biguanide for the treatment of patients with NIDDM that are refractory to dietary management alone. Metformin does not affect insulin secretion but requires the presence of insulin to be effective. The exact mechanism of metformin’s action is not clear, but it does decrease hepatic glucose production and increase peripheral glucose uptake. When used as monotherapy, metformin rarely causes hypoglycemia.

Definition

ChEBI: Metformin is a member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1. It has a role as a hypoglycemic agent, a xenobiotic, an environmental contaminant and a geroprotector. It is functionally related to a biguanide. It is a conjugate base of a metformin(1+).

Biological Functions

Metformin can lower free fatty acid concentrations by 10 to 30%. This antilipolytic effect may help to explain the reduction in gluconeogenesis through reduced levels of available substrate (65). When given as a monotherapy, metformin treatment does not lead to hypoglycemia, so it is better described as an antihyperglycemic agent rather than a hypoglycemic agent.

Mechanism of action

The mechanism of action of biguanides is still not fully understood. Three major tissues have been identified as pharmacological sites of action: (1) the small intestinal wall, (2) the liver, and (3) peripheral tissues, mainly the skeletal muscle: 1. For the small intestine an inhibition of glucose absorption was described, however, this is, at least for metformin, of minor significance and not important for the blood glucose lowering effect. However, the intestinal glucose metabolization to lactate is stimulated and reduces the postprandial uptake of glucose by the liver. 2. Numerous studies have shown that biguanides inhibit hepatic gluconeogenesis and this may contribute to the blood glucose lowering effect, particularly in the fasting state. Again, metformin has probably less impact on gluconeogenesis than phenformin and buformin. 3. In the peripheral tissues, metformin increases the glucose disposal and utilization particularly in the skeletal muscle, which is probably the major contribution to the blood glucose lowering activity. In vitro studies using cell cultures have shown that metformin potentiates insulin action. In vivo studies in animals and diabetic patients have demonstrated that metformin reduces insulin resistance, at least in obese individuals.

Clinical Use

Metformin works best in patients with significant hyperglycemia and is often considered first-line therapy in the treatment of mild to moderate type II overweight diabetics who demonstrate insulin resistance. The United Kingdom Prospective Diabetes Study demonstrated a marked reduction in cardiovascular comorbidities and diabetic complications in metformintreated individuals. Metformin has also been used to treat hirsutism in individuals with polycystic ovarian syndrome and may enhance fertility in these women, perhaps by decreasing androgen levels and enhancing insulin sensitivity.

Safety Profile

Poison by subcutaneous and intraperitoneal routes. Mildly toxic by parenteral route. Experimental teratogenic effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx

Metabolism

Metformin is quickly absorbed from the small intestine. Bioavailability is from 50 to 60%, and the drug is not protein bound. Peak plasma concentrations occur at approximately 2 hours. The drug is widely distributed in the body and accumulates in the wall of the small intestine. This depot of drug serves to maintain plasma concentrations. Metformin is excreted in the urine, via tubular excretion, as unmetabolized drug with a half-life of approximately 2 to 5 hours; therefore, renal impairment as well as hepatic disease are contraindications for the drug.

Metformin Preparation Products And Raw materials

Raw materials

dicyanamide Hydrochloric acid Dimethylamine

Preparation Products

N,N-Dimethyl-1,3,5-triazine-2,4-diamine Metformin hydrochloride

Metformin Suppliers

Global( 168)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
J S LABS	+91-7330612784 +91-7330612784	Tamil Nadu, India	160	58	Inquiry
AARTIA KEM SCIENCE	+91-8291072530 +91-8291072530	Maharashtra, India	70	58	Inquiry
Sun Pharmaceutical Industries Ltd	+91-2242244224 +91-2243244324	Maharashtra, India	108	58	Inquiry
Smilax Laboratories Limited	+91-8919514965 +91-8008333438	Telangana, India	28	58	Inquiry
HRV Global Life Sciences	+91-9820219686 +91-9820219686	Telangana, India	379	58	Inquiry
Harman Finochem Ltd	+91-2226528080 +91-2226528080	Maharashtra, India	37	58	Inquiry
Besil Chem LLP	+91-7760252666 +91-9880731835	Bangalore, India	163	58	Inquiry
Humble Healthcare Limited	+91-9720093000 +91-8006400378	Uttar Pradesh, India	141	58	Inquiry
Wanbury Limited	+91-2271963222 +91-2267942222	Maharashtra, India	17	58	Inquiry
Syglak Laboratories Pvt Ltd	+91-7506010127 +91-7506010127	Maharashtra, India	17	58	Inquiry

Supplier	Advantage
J S LABS	58
AARTIA KEM SCIENCE	58
Sun Pharmaceutical Industries Ltd	58
Smilax Laboratories Limited	58
HRV Global Life Sciences	58
Harman Finochem Ltd	58
Besil Chem LLP	58
Humble Healthcare Limited	58
Wanbury Limited	58
Syglak Laboratories Pvt Ltd	58

Metformin Spectrum

Metformin(657-24-9)¹HNMR

657-24-9(Metformin)Related Search:

Colesevelam Miglitol Repaglinide Acarbose Ascorbic Acid

Gliclazide Paroxetine Icotinib Saxagliptin Trelagliptin

Pregabalin Ibrutinib Troglitazone Sofosbuvir Metformin hydrochloride

Biguanide Metformin

chevron_left

1of4

chevron_right

1,1-dimethyl-biguanid dmgg flumamine gliguanid haurymelin la6023 melbin n,n-dimethylbiguanide n,n-dimethyldiguanide n,n-dimethyl-imidodicarbonimidicdiamid nndg 1-Carbamimidamido-N,N-dimethylmethanimidamide Metformin MetforMin-d6 HCl meformin hcl MetforminHclBp N,N-Dimethylimidodicarbonimidic diamide Imidodicarbonimidic diamide, N,N-dimethyl- Metformin HCL (IP/BP/USP) Metformin USP/EP/BP Metformin powder Metformin /Metformin HCl Metformin-1 gram MetforminQ: What is Metformin Q: What is the CAS Number of Metformin Q: What is the storage condition of Metformin Q: What are the applications of Metformin dimethylbiguanide METFORMIN BASE Metformine Phenytoin Impurity 16 Fluamine 657-24-9 657-24-9